These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 26121203

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
    Frymoyer A, Guglielmo BJ, Hersh AL.
    Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED, Herald M, Koura F.
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [Abstract] [Full Text] [Related]

  • 5. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
    Hale CM, Seabury RW, Steele JM, Darko W, Miller CD.
    J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
    [Abstract] [Full Text] [Related]

  • 6. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
    Prybylski JP.
    Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475
    [Abstract] [Full Text] [Related]

  • 7. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
    Tkachuk S, Collins K, Ensom MHH.
    Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
    [Abstract] [Full Text] [Related]

  • 8. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S, Tsuji Y, Mizoguchi A, Kasai H, Ishibashi T, Iwamura N, To H.
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [Abstract] [Full Text] [Related]

  • 9. Vancomycin dosing and target attainment in children.
    Hwang D, Chiu NC, Chang L, Peng CC, Huang DT, Huang FY, Chi H.
    J Microbiol Immunol Infect; 2017 Aug; 50(4):494-499. PubMed ID: 26462708
    [Abstract] [Full Text] [Related]

  • 10. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O, Al Omar S, Nazer LH, Mubarak S, Le J.
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic Monitoring of Vancomycin in Cystic Fibrosis: Is It Time to Move Past Trough Concentrations?
    Fusco NM, Prescott WA, Meaney CJ.
    Pediatr Infect Dis J; 2019 Mar; 38(3):258-262. PubMed ID: 29742643
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Improved vancomycin dosing in children using area under the curve exposure.
    Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, Cho S, Natale S, Bui I, Tran TM, Capparelli EV.
    Pediatr Infect Dis J; 2013 Apr; 32(4):e155-63. PubMed ID: 23340565
    [Abstract] [Full Text] [Related]

  • 16. Vancomycin Therapeutic Targets and Nephrotoxicity in Critically Ill Children With Cancer.
    Seixas GT, Araujo OR, Silva DC, Arduini RG, Petrilli AS.
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):e56-62. PubMed ID: 26558810
    [Abstract] [Full Text] [Related]

  • 17. Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.
    Hsu AJ, Hamdy RF, Huang Y, Olson JA, Ghobrial S, Gerber JS, Hersh AL, Tamma PD.
    J Pediatric Infect Dis Soc; 2018 Dec 03; 7(4):338-341. PubMed ID: 28992126
    [Abstract] [Full Text] [Related]

  • 18. Association of Vancomycin AUC/MIC and Trough Concentration With Early Clinical Response in Enterococcus or Coagulase-Negative Staphylococcus Infection: A Prospective Study.
    Pitayakittiwong C, Sermsappasuk P, Meesing A, Jaisue S.
    J Clin Pharmacol; 2024 Aug 03; 64(8):1006-1014. PubMed ID: 38639115
    [Abstract] [Full Text] [Related]

  • 19. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y, Song KH, Cho Je, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD.
    Int J Antimicrob Agents; 2014 Feb 03; 43(2):179-83. PubMed ID: 24315788
    [Abstract] [Full Text] [Related]

  • 20. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
    Suchartlikitwong P, Anugulruengkitt S, Wacharachaisurapol N, Jantarabenjakul W, Sophonphan J, Theerawit T, Chatsuwan T, Wattanavijitkul T, Puthanakit T.
    J Clin Pharmacol; 2019 Dec 03; 59(12):1597-1605. PubMed ID: 31342543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.